Race, Trust, and COVID-19 Vaccine Hesitancy in People with Opioid Use Disorder
Overview
Authors
Affiliations
Objective: Vaccination against coronavirus disease 2019 (COVID-19) is a promising avenue for arresting the COVID-19 pandemic, yet suboptimal rates of vaccine uptake in at-risk groups may hinder efficacy and worsen existing health disparities. People with opioid use disorder (OUD) are likely to face increased vulnerability to COVID-19 due to a confluence of biological and social risk factors. We sought to assess factors associated with willingness to vaccinate against COVID-19 in people with OUD.
Method: Phone surveys were conducted from May to October 2020 with participants enrolled in an urban methadone maintenance program (MMP). Participants were adults who met criteria for OUD and reported injection drug use or sexual risk behavior. Participants were asked about their willingness to receive a highly or partially effective vaccine. Provider trust was assessed using the Trust in Physician scale. Multinomial regression was used to assess demographic and psychosocial factors related to vaccination willingness.
Results: We surveyed 109 people with OUD enrolled in a MMP ( = 47 years; 56% women; 59% White, 23% Black/African American, 14.4% Hispanic/Latinx; 1.8% other). Participants who identified as Black or African American were significantly less likely to endorse willingness to use a partially effective COVID-19 vaccine (adjusted odds ratio [] = .10; 95% confidence interval (CI) [.02, .61], p = .012), although not necessarily less willing to receive a highly effective vaccine ( = .40; 95% CI [.09, 1.73], = .219; .). Trust in physician was positively associated with willingness to use a partially effective vaccine ( = 1.12; 95% CI [1.02, 1.23], = .017), but was not significantly associated with willingness to receive a highly effective vaccine ( = 1.07; 95% CI [.98, 1.16], = .162, ) Conclusions: Proactive outreach from trustworthy sources will be needed to counter vaccine hesitancy in people with OUD, especially among Black Americans with OUD. (PsycInfo Database Record (c) 2022 APA, all rights reserved).
Gonzalez-Jaramillo N, Abbuhl D, Roa-Diaz Z, Kobler-Betancourt C, Frahsa A BMJ Open. 2024; 14(4):e084560.
PMID: 38631831 PMC: 11029206. DOI: 10.1136/bmjopen-2024-084560.
Predictors of COVID-19 vaccine uptake among people who use substances: a case study in Tehran.
Karimi S, Amadi S, Rampisheh Z, Tayefi B, SoleimanvandiAzar N, Higgs P Subst Abuse Treat Prev Policy. 2024; 19(1):15.
PMID: 38409120 PMC: 10895917. DOI: 10.1186/s13011-024-00596-9.
Artna E, Abi-Jaoude A, Sockalingam S, Perry C, Johnson A, Wun C BMJ Open. 2024; 14(1):e080707.
PMID: 38238177 PMC: 10806589. DOI: 10.1136/bmjopen-2023-080707.
Specka M, Krockert T, Trilling M, Bonnet U, Schifano F, Scherbaum N Front Psychiatry. 2023; 14:1254053.
PMID: 37779618 PMC: 10539610. DOI: 10.3389/fpsyt.2023.1254053.
Parameswaran L, Jaysing A, Ding H, Wilkenfeld M, Dean R, Wilson K J Racial Ethn Health Disparities. 2023; 11(4):2109-2119.
PMID: 37391605 DOI: 10.1007/s40615-023-01680-9.